Fitch Affirms BBB+ Rating on Agilent's $2.8B of Debt | GenomeWeb

NEW YORK (GenomeWeb News) – Fitch Ratings today affirmed BBB+ ratings for about $2.8 billion of Agilent Technologies' debt, noting the firm's ongoing revenue diversification and conservative financial policies.

Fitch issued BBB+ ratings on Agilent's issuer default rating, senior unsecured revolving credit facility, and senior unsecured notes. The ratings affect about $2.8 billion of debt, including an undrawn $400 million revolving credit facility that expires in 2016, the ratings firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.